Puriblood Medical Co Ltd

Puriblood Medical Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.31, indicating a relatively low reliance on debt financing. The company holds TWD 60.4 million in cash and equivalents, which exceeds its TWD 43.2 million in long-term debt, suggesting strong liquidity coverage. However, the company reported negative operating cash flow of TWD 27.4 million in the latest period, which may signal near-term cash flow constraints. Profitability metrics show mixed performance. The company's revenue of TWD 82.3 million in the latest period is below the median for its industry, and the negative operating cash flow suggests operational inefficiencies or high R&D investment. While the debt-to-equity ratio is favorable, the lack of positive cash flow from operations raises concerns about long-term sustainability without external financing. Geographically, Puriblood's revenue is not disclosed by region, but its operations are based in Taiwan, which may expose it to regional supply chain and regulatory risks. The company's product portfolio is concentrated in blood purification equipment, with no disclosed diversification into other medical device categories. Looking ahead, the company's revenue outlook is constrained by its current financial position. With no disclosed revenue growth in the latest period and negative operating cash flow, the company may face challenges in scaling operations without additional capital. The absence of disclosed capital expenditures beyond TWD 479,000 suggests a low level of investment in expansion or R&D. Risk factors include liquidity pressure from negative operating cash flow and the potential for dilution if the company raises additional capital. The company has not disclosed any immediate dilution risks, and its shares outstanding remain unchanged between basic and diluted shares. However, the low liquidity risk score and absence of filing-based flags suggest no imminent financial distress. Recent filings and transcripts do not disclose material events or strategic shifts. The company's focus remains on its core blood purification products, with no new product launches or partnerships reported in the latest available data.